Le sale conferenze Motus Animi

venerdì 6 settembre 2019

What’s next in multiple myeloma? Catania, September 23,2019



“What’s next in multiple myeloma?”
Catania, September 23,2019

Aula CAST
A.O.U. Policlinico Universitario “Gaspare Rodolico”
Via Santa Sofia, 78 - Catania


Scientific Board: F. Di Raimondo - G. A. Palumbo

Scientific Secretariat:  C. Conticello - A. Romano 
Monday, September  23, 2019

08:30               
Registration of Participants
Introduction
Francesco Di Raimondo (Catania)
I SESSION
NOVEL INSIGHTS IN CLINICAL MANAGEMENT OF MYELOMA PATIENTS
Chairmen: Maurizio Musso (Palermo), Caterina Musolino (Messina) 
09:00            
Up-front treatment in myeloma patients in 2019
Alessandro Corso (Pavia)

09:20               
Treatment of relapsing/refractory patients
Massimo Offidani (Ancona)

09:40            
Strategies for relapses beyond the 2nd  line: patient profiling
Marco Rossi (Catanzaro)

10:00              
Immunotherapy in multiple myeloma
Massimo Massaia (Cuneo)

10:20               
Discussion on previous sessions

10:30              
Coffee Break

II SESSION
Novel insights in Myeloma biology
Chairmen: Donato Mannina (Messina), Sergio Siragusa (Palermo)

11:00               
Non-neutral clonal evolution in Multiple Myeloma
Carolina Terragna (Bologna)

11:20               
Non-coding genomic aberrations in Multiple Myeloma
Antonino Neri (Milano)

11:40               
Role of microenvironment dysfunction in promoting Multiple Myeloma
Angelo Vacca (Bari)

12:00 
Epigenetics in multiple myeloma"?                    
Aldo Roccaro (Brescia)

12:20               
Modelling myeloma to predict clinical outcome by systems thinking
Francesco Gonella, Alessandra Romano (Venezia, Catania)

12:50               
Discussion on previous sessions

13:10               
Light Lunch

 III SESSION
Novel insights in Myeloma diagnosis and prognosis 
Chairmen: Pellegrino Musto (Rionero in Vulture), Ugo Consoli (Catania)

14:10               
The role of FISH in the management of multiple myeloma               
Paola Omedè (Torino)

14:30                           
The role of next-generation sequencing in the management of multiple    myeloma
Niccolò Bolli (Milano)

14:50               
Minimal residue disease: how and when to detect?
Bruno Paiva (Pamplona)

15:10               
A network experience in lymphoproliferative diseases: the case of BCL-2 monitoring
Marco Ladetto (Alessandria)


15.30              
The Sicilian Myeloma Network experience
Etta Conticello (Catania)

15,40              
How to deal with the sustainability of the new drugs costs
Federico Spandonaro (Roma)

15:50               
Discussion on previous sessions

16:00               
Coffee break


16:15-17:30  Interactive session

Participants will be divided in four groups

GROUP A:
Immunophenotyping in myeloma: circulating plasma cells and minimal residual disease
Tutor Laura Parrinello (Catania)

GROUP B:       
Immune cells in multiple myeloma: MDSC and T-cell sub-populations
Tutor Ciro Botta (Catanzaro)

GROUP C:
CD138+ cells enrichment and molecular assays
Tutor Daniele Tibullo (Catania)

GROUP D:       
Ethical and administrative requirements for multicentric trials
Tutor Vittorio Del Fabro and Marco Ragusa (Catania)

16.30
Test ECM and Conclusion